Safety and efficacy of the Oxford-AstraZeneca vaccine against SARS-CoV-2 after 2nd and 3rd dose in adults: a cross-sectional study
Background: The rapid global spread of the coronavirus SARS-CoV-2 and the lack of established therapeutic choices led to development of several vaccines. Our aim was to investigate the safety and effectiveness of the Oxford-AstraZeneca adenovirus vectored vaccine against SARS-CoV-2 breakthrough infe...
Saved in:
Main Authors: | Shahrbanoo Sedigh Sarooni, Malihe Mohammadi, Seyed Mohammad Riahi |
---|---|
Format: | Article |
Language: | English |
Published: |
Medical University of Gdańsk
2024-12-01
|
Series: | European Journal of Translational and Clinical Medicine |
Subjects: | |
Online Access: | https://ejtcm.gumed.edu.pl/articles/196493.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.
by: E. V. Shlyakhto, et al.
Published: (2023-07-01) -
New Tendencies in the Development of the EU Competition Law – the AstraZeneca case
by: K. V. Entin
Published: (2011-10-01) -
Middle Cerebral Artery Dissection after AstraZeneca COVID-19 Vaccination
by: Hsin-Wei Wu, et al.
Published: (2025-04-01) -
Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection
by: Zdzisława Kondera-Anasz, et al.
Published: (2025-07-01) -
Biochemical Action of Vaccines in Iraqi Patients with COVID-19 Infection
by: Rasha Zuhair Jasim
Published: (2023-08-01)